Adair Jason sold $60K of LQDA

Adair Jason (Chief Business Officer) sold 688 shares of Liquidia Corp (LQDA) at $87.53 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Jul 29, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure confirms the transaction details (shares, price, date, and post-sale holdings) but does not include any new company-specific fundamental catalyst.

02

Market read

Traders may log the event for sentiment tracking, but it is unlikely to drive price action without additional corroborating news.

03

What to watch

10b5-1 plans reduce interpretability; the article does not state whether additional sales occurred under the same plan or whether the insider’s remaining holdings changed materially beyond the post-transaction figure.

Relevance 2/10Novelty 2/10Timing: SEC Form 4 filed 2026-07-29, covering a sale executed 2026-07-27.

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by its Chief Business Officer, Adair Jason, with a stated pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Adair Jason, Chief Business Officer, sold 688 shares at $87.53 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only unless paired with other new fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and the article contains no accompanying operational or guidance change.

Market effects

No clear sector read-through; this is a single-company insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

A large insider sale can still be worth monitoring if it coincides with other negative developments, but none are provided here.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Adair Jason

    Chief Business Officer who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.